rest of the world
- PEG-Riba gives 70% SVR in G3, 50% SVR in G1 which can be increased to 70-80% with addition of generation 1 protease inhibitors boceprevir or telaprevir, but with major additional side effects.
- Pharmasset bought out by Gilead for USD11 billion late 2011 on basis of a phase 2 trial result with sofosbuvir
Biotron
- 4 weeks of BIT225 added to standard PEG-Riba leads to modest increase in SVR of similar magnitude to telaprevir and boceprevir in a phase 1/2a trial
2016:
rest of the world
- sofosbuvir, sofosbuvir/ledipasvir, simeprevir, daclatasvir, Viekira all licensed by FDA to treat HCV without PEG-Riba with SVR rates of 95-100% without any major side effects
- although prices in US peaked at over USD100,000 per course, increased competition is driving down prices, and generics of most of these drugs can be purchased from India/China for $2000 a course
- PEG-Riba is no longer used in any first world country except New Zealand
Biotron
- 12 weeks of BIT225 added to standard PEG-Riba leads to similar rates of SVR as a 4 week course of BIT225
Lack of adequate funding has resulted in Biotron crawling through clinical trials in the fastest moving area of medicine. and missing the boat with HCV. It can't let the same thing happen with HIV or it will cease to be a going concern.
BIT Price at posting:
7.3¢ Sentiment: Sell Disclosure: Not Held
